{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(5)"],"submitter":["Weiss R"],"pubmed_abstract":["<h4>Introduction</h4>Acute kidney injury (AKI) is a common complication in cardiac surgery patients and prevention is needed to improve clinical outcomes. Alpha-1-microglobulin (A1M) is a physiological antioxidant with strong tissue-protective and cell-protective properties that has demonstrated renoprotective effects. RMC-035, a recombinant variant of endogenous human A1M, is being developed for the prevention of AKI in cardiac surgery patients.<h4>Methods</h4>In this phase 1b, randomized, double-blind, and parallel group clinical study, 12 cardiac surgery patients undergoing elective, open-chest, on-pump coronary artery bypass graft and/or valve surgery with additional predisposing AKI risk factors were enrolled to receive in total 5 intravenous doses of either RMC-035 or placebo. The pr"],"journal":["Kidney international reports"],"pagination":["980-988"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10166741"],"repository":["biostudies-literature"],"pubmed_title":["Recombinant Alpha-1-Microglobulin (RMC-035) to Prevent Acute Kidney Injury in Cardiac Surgery Patients: Phase 1b Evaluation of Safety and Pharmacokinetics."],"pmcid":["PMC10166741"],"pubmed_authors":["von Groote T","Weiss R","Agervald T","Wempe C","Zarbock A","Meersch M"],"additional_accession":[]},"is_claimable":false,"name":"Recombinant Alpha-1-Microglobulin (RMC-035) to Prevent Acute Kidney Injury in Cardiac Surgery Patients: Phase 1b Evaluation of Safety and Pharmacokinetics.","description":"<h4>Introduction</h4>Acute kidney injury (AKI) is a common complication in cardiac surgery patients and prevention is needed to improve clinical outcomes. Alpha-1-microglobulin (A1M) is a physiological antioxidant with strong tissue-protective and cell-protective properties that has demonstrated renoprotective effects. RMC-035, a recombinant variant of endogenous human A1M, is being developed for the prevention of AKI in cardiac surgery patients.<h4>Methods</h4>In this phase 1b, randomized, double-blind, and parallel group clinical study, 12 cardiac surgery patients undergoing elective, open-chest, on-pump coronary artery bypass graft and/or valve surgery with additional predisposing AKI risk factors were enrolled to receive in total 5 intravenous doses of either RMC-035 or placebo. The pr","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 May","modification":"2026-05-28T18:38:39.931Z","creation":"2025-02-19T04:55:43.449Z"},"accession":"S-EPMC10166741","cross_references":{"pubmed":["37180511"],"doi":["10.1016/j.ekir.2023.02.1071"]}}